Robyn M. Scherber, MD, MPH, discusses her advice for treating patients with myelofibrosis that become refractory or resistant to ruxolitinib.
Robyn M. Scherber, MD, MPH, a physician at Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discussesher advice for treating patients with myelofibrosis(MF) that become refractory or resistant to ruxolitinib (Jakifi).
Ruxolitinib should be maximized in patients with MF as it is known to have spleen response, symptom response, and patients also tend to feel better on it. Scherber says optimizing ruxolitinib is key. However, she has seen physicians try to dose down at the first sign of concerning anemia. Erythropoietin or danazol can be used to help treat anemia in these patients.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More